Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNC ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TNC Products |
| Gene Delivery | TNC Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TNC Products |
| Benchmark Ab | Anti-TNC (Sequence of Benchmark) Recombinant positive control. |
View TNC Products |
| Validator | TNC siRNA Set For knockdown verification. |
View TNC Products |
| Related Target A | FN1 Tumor microenvironment extracellular matrix partner |
View FN1 Products |
| Related Target B | ITGB1 Receptor interacting with Tenascin-C to drive metastasis |
View ITGB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extracellular Matrix Isoform specificity | Human/Mouse/Cyno ortholog proteins available with >95% purity, Sequence Verified |
| High Background in Stroma binding assays | HEK293 Expressed (Native Glycosylation), Endotoxin Controlled |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live TNC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNC therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and Radiopharmaceuticals. As first-generation therapies reach the clinic, the next wave of R&D is targeting optimized tumor microenvironment (TME) penetration and stroma-directed combination therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Philogen, Novartis | Glioblastoma, Solid Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| Radioligand | Bayer, Various Biotech | Prostate Cancer, Lymphoma | High-Affinity Binding (Need HEK293 Expressed Protein) |
| Bispecific | Roche, Amgen | Immunotherapy | Heterodimer Validation (Need Cross-reactive Abs) |